Company Name, Ticker, Industry, else..

Atrium Therapeutics Inc (NASDAQ: RNA)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Atrium Therapeutics Inc 's

Name: Atrium Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RNA Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Atrium Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -21.91 %, despite the revenue increase by the most of its competitors of 3.99 %, recorded in the same quarter.

• List of RNA Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Atrium Therapeutics Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< RNA Stock Performance Comparisons

<< See the full list of RNA competitors

Overall company Market Share Q2 2026

Overall company, revenue fell by -21.91 % and company lost market share, to approximately 0.02 %. << More on RNA Market Share.

*Market share is calculated based on total revenue.

RNA's Stock Performance relative to its Competitors

Publicly Traded Peers of Atrium Therapeutics Inc

Centessa Pharmaceuticals Plc
Share Performance

+43.52%

This Quarter

Centessa Pharmaceuticals Plc

Profile

Centessa Pharmaceuticals Plc operates as a biopharmaceutical company that focuses on the discovery and development of innovative medicines. Their business model centers around leveraging a decentralized approach, with multiple subsidiary companies working autonomously to accelerate the research and development of potential therapeutics across various disease areas. By bringing together diverse expertise and resources, Centessa aims to efficiently advance breakthrough therapies and deliver impactful solutions to patients in need.

More about Centessa Pharmaceuticals Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 6,218.764 mill.	$ - mill.	$ -250.638 mill.

Igm Biosciences Inc
Share Performance

0.00%

Over The Past 5 Days

Igm Biosciences Inc

Profile

Igm Biosciences Inc's business model focuses on the discovery and development of engineered Immunoglobulin M (IgM) antibodies to treat various diseases, primarily cancer.

More about Igm Biosciences Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 78.424 mill.	$ 145.048 mill.	$ -53.385 mill.

Ionis Pharmaceuticals Inc
Share Performance

+7.27%

30 Days

Ionis Pharmaceuticals Inc

Profile

Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success.

More about Ionis Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,615.806 mill.	$ 1,169.419 mill.	$ -313.017 mill.

Kyntra Bio Inc
Share Performance

+24.12%

This Quarter

Kyntra Bio Inc

Profile

The company conducts preclinical development and clinical trials for its product candidates.

More about Kyntra Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 34.368 mill.	$ - mill.	$ 183.192 mill.

Mirum Pharmaceuticals Inc
Share Performance

+9.18%

This Quarter

Mirum Pharmaceuticals Inc

Profile

Mirum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing innovative therapies for patients with rare liver diseases.

More about Mirum Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 5,922.178 mill.	$ 569.609 mill.	$ -798.841 mill.

42 more competitors available

Sources: Atrium Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 3, 2026 11:56 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Atrium Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.